Cognition Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing zervimesine for neurodegenerative diseases. Its Form 8-K reports cover financial results, Regulation FD presentations, clinical-development announcements, FDA meeting disclosures, and material agreements, including an at-the-market common-stock sales arrangement.
Proxy materials disclose annual meeting and stockholder voting matters, while registration and current-report disclosures identify the company’s Delaware corporate status, emerging growth company reporting status, and Nasdaq-listed common stock. The filings also provide formal records of capital-structure activity, governance processes, and risk areas associated with clinical research, regulatory review, grant funding, and the financing needs of a development-stage biotechnology company.
Cognition Therapeutics’ Q1 2026 report shows a smaller loss while it continues advancing its neurology pipeline. Net loss narrowed to $4,570 thousand, or $0.05 per share, compared with $8,480 thousand, or $0.14 per share, a year earlier. Operating expenses fell as research and development dropped to $6,120 thousand from $10,786 thousand, reflecting lower clinical program and personnel costs.
The company generated $3,979 thousand of grant income, mainly from U.S. National Institute on Aging awards funding its Alzheimer’s and dementia with Lewy bodies studies. Cash, cash equivalents and restricted cash totaled $31.2 million, and management believes this, together with existing NIA grant support, can fund operations through the second quarter of 2027. Lead candidate zervimesine (CT1812) remains in multiple Phase 2 programs for Alzheimer’s disease and DLB, with large NIA grants and a 2025 shelf registration and at-the-market program providing additional financing flexibility.
Cognition Therapeutics reported first-quarter 2026 results and a business update focused on its lead candidate zervimesine. Cash, cash equivalents and restricted cash were about $31.2 million as of March 31, 2026, with $25.6 million of obligated grant funds remaining, and the company estimates its cash will fund operations through the second quarter of 2027.
Research and development expenses fell to $6.1 million from $10.8 million a year earlier, while general and administrative expenses declined to $2.7 million from $3.0 million. Net loss narrowed to $4.6 million, or $(0.05) per share, compared with $8.5 million, or $(0.14) per share, on higher grant and other income.
The company highlighted a scheduled May 20, 2026 meeting with the FDA’s Division of Psychiatry to discuss a potential registrational study of zervimesine in dementia with Lewy body psychosis and reiterated that topline results from the 545-participant Phase 2 START Alzheimer’s study are anticipated in 2027.
Cognition Therapeutics Inc. Chief Financial Officer John Brendan Doyle reported a routine tax-related share disposition. On the vesting of restricted stock units, the company withheld 8,567 shares of common stock at $1.28 per share to cover tax withholding obligations. After this non-market transaction, Doyle directly holds 618,942 shares of Cognition Therapeutics common stock, indicating he retains a substantial equity stake following the RSU vesting.
Cognition Therapeutics, Inc. is asking stockholders to vote at its 2026 Annual Meeting, held virtually on June 17, 2026 at 9:00 a.m. Eastern. Holders of common stock at the close of business on April 20, 2026 (89,353,773 shares outstanding) may vote.
Stockholders will elect two Class II directors, Aaron Fletcher, Ph.D. and Lisa Ricciardi, to terms expiring in 2029, and ratify Ernst & Young LLP as independent registered public accounting firm for 2026. The six‑member board includes five independent directors and an independent chair.
The proxy also outlines corporate governance practices, committee structures, director pay, and 2025 executive compensation. In 2025, CEO Lisa Ricciardi received total compensation of about $1.46 million, including salary, RSUs and a performance bonus. The filing highlights recent clinical progress in dementia with Lewy bodies and Alzheimer’s disease.
Cognition Therapeutics Chief Financial Officer John Brendan Doyle bought 10,000 shares of common stock in an open-market purchase at $1.13 per share. The transaction involved directly held shares. Following this purchase, Doyle directly owns a total of 627,509 shares of Cognition Therapeutics common stock.
Cognition Therapeutics Inc CEO and President Lisa Ricciardi reported an open-market purchase of 9,175 shares of common stock at $1.10 per share on April 16, 2026. After this transaction, she directly holds 1,715,851 shares and indirectly holds 38,851 shares through her spouse.
Cognition Therapeutics Inc. Chief Medical Officer Anthony Caggiano reported an open-market purchase of 10,000 shares of the company’s Common Stock on April 16, 2026 at a price of $1.11 per share. Following this transaction, his direct holdings increased to 874,906 shares of Common Stock.
Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs for age‑related degenerative diseases of the central nervous system and retina. Its lead candidate, zervimesine (CT1812), targets toxic protein oligomers implicated in Alzheimer’s disease, dementia with Lewy bodies and dry age‑related macular degeneration.
Zervimesine has shown cognitive and functional benefits in multiple Phase 1 and 2 studies and holds FDA Fast Track designation for Alzheimer’s disease. The pipeline is heavily supported by non‑dilutive funding, with about $171 million in cumulative grants, including major awards from the National Institute on Aging.
The company reports 10 issued U.S. patents and broad international filings around zervimesine, with core composition‑of‑matter protection projected into 2035 and potential extensions. As of March 1, 2026, it had 14 employees and continued to progress late‑stage trials and regulatory interactions in Alzheimer’s and Lewy body dementia.
Cognition Therapeutics reported improved 2025 results with a smaller loss and stronger balance sheet while advancing its neurology pipeline. For the year ended December 31, 2025, the company recorded a net loss of $23.5 million, or $(0.32) per share, compared with a net loss of $34.0 million, or $(0.86) per share in 2024.
Research and development expenses fell to $37.2 million from $41.7 million, and general and administrative expenses declined to $10.6 million from $12.3 million, reflecting lower clinical and stock-based compensation costs. Grant income increased to $23.4 million.
Cash, cash equivalents, and restricted cash were $37.0 million as of December 31, 2025, with remaining obligated grant funds of $35.7 million. The company estimates its cash will fund operations and capital spending through the second quarter of 2027. Clinically, it completed enrollment in the Phase 2 START Alzheimer’s study, reported strong Phase 2 SHIMMER data in DLB, launched an expanded access program for DLB, and is planning a mid-2026 FDA Division of Psychiatry meeting to align on a registrational path for zervimesine in DLB psychosis.